Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-grade ovarian cancer (HGOC). The efficacy and safety of rucaparib after PARPi therapy are largely unknown; therefore, we analyzed outcomes in the subgrou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yubero, Alfonso, Estévez, Purificación, Barquín, Aránzazu, Sánchez, Luisa, Santaballa, Ana, Pajares, Bella, Reche, Piedad, Salvador, Carmen, Manso, Luis, Márquez, Raúl, González-Martín, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314222/
https://www.ncbi.nlm.nih.gov/pubmed/37396679
http://dx.doi.org/10.1016/j.gore.2023.101211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314222/
https://www.ncbi.nlm.nih.gov/pubmed/37396679
http://dx.doi.org/10.1016/j.gore.2023.101211

Ejemplares similares